Glycemic Control and Bone in Diabetes.

IF 4.2 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Current Osteoporosis Reports Pub Date : 2022-12-01 DOI:10.1007/s11914-022-00747-6

David R Weber, Fanxin Long, Babette S Zemel, Joseph M Kindler

{"title":"Glycemic Control and Bone in Diabetes.","authors":"David R Weber, Fanxin Long, Babette S Zemel, Joseph M Kindler","doi":"10.1007/s11914-022-00747-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review summarizes recent developments on the effects of glycemic control and diabetes on bone health. We discuss the foundational cellular mechanisms through which diabetes and impaired glucose control impact bone biology, and how these processes contribute to bone fragility in diabetes.Recent findings: Glucose is important for osteoblast differentiation and energy consumption of mature osteoblasts. The role of insulin is less clear, but insulin receptor deletion in mouse osteoblasts reduces bone formation. Epidemiologically, type 1 (T1D) and type 2 diabetes (T2D) associate with increased fracture risk, which is greater among people with T1D. Accumulation of cortical bone micro-pores, micro-vascular complications, and AGEs likely contribute to diabetes-related bone fragility. The effects of youth-onset T2D on peak bone mass attainment and subsequent skeletal fragility are of particular concern. Further research is needed to understand the effects of hyperglycemia on skeletal health through the lifecycle, including the related factors of inflammation and microvascular damage.","PeriodicalId":11080,"journal":{"name":"Current Osteoporosis Reports","volume":"20 6","pages":"379-388"},"PeriodicalIF":4.2000,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549036/pdf/","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Osteoporosis Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11914-022-00747-6","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 2

Abstract

Purpose of review: This review summarizes recent developments on the effects of glycemic control and diabetes on bone health. We discuss the foundational cellular mechanisms through which diabetes and impaired glucose control impact bone biology, and how these processes contribute to bone fragility in diabetes.

Recent findings: Glucose is important for osteoblast differentiation and energy consumption of mature osteoblasts. The role of insulin is less clear, but insulin receptor deletion in mouse osteoblasts reduces bone formation. Epidemiologically, type 1 (T1D) and type 2 diabetes (T2D) associate with increased fracture risk, which is greater among people with T1D. Accumulation of cortical bone micro-pores, micro-vascular complications, and AGEs likely contribute to diabetes-related bone fragility. The effects of youth-onset T2D on peak bone mass attainment and subsequent skeletal fragility are of particular concern. Further research is needed to understand the effects of hyperglycemia on skeletal health through the lifecycle, including the related factors of inflammation and microvascular damage.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

糖尿病的血糖控制和骨骼。

综述目的:本文综述了近年来血糖控制和糖尿病对骨骼健康影响的研究进展。我们讨论了糖尿病和葡萄糖控制受损影响骨生物学的基本细胞机制，以及这些过程如何导致糖尿病患者的骨脆性。近期研究发现:葡萄糖在成骨细胞分化和成熟成骨细胞能量消耗中起重要作用。胰岛素的作用尚不清楚，但小鼠成骨细胞中胰岛素受体的缺失会减少骨形成。流行病学上，1型(T1D)和2型糖尿病(T2D)与骨折风险增加有关，在T1D患者中更大。皮质骨微孔的积累、微血管并发症和AGEs可能导致糖尿病相关的骨脆性。青年发病的T2D对骨量达到峰值和随后的骨骼脆性的影响尤其值得关注。需要进一步的研究来了解高血糖对整个生命周期骨骼健康的影响，包括炎症和微血管损伤的相关因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Osteoporosis Reports Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

8.80

自引率

2.30%

发文量

期刊介绍： This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of osteoporosis. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as current and future therapeutics, epidemiology and pathophysiology, and evaluation and management. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.